Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

AstraZeneca and Heptares Collaborate to Investigate Important GPCR Drug Targets

By Pharmaceutical Processing | May 31, 2011

 

AstraZeneca and Heptares Therapeutics today announced they
have entered a four-year collaboration focused on the potential discovery and
development of new medicines targeting G-protein coupled receptors (GPCRs).

GPCRs are among the largest and most important family of
proteins found in the human body, yet they become highly unstable when removed
from their natural membrane-bound environments. This instability has prevented
pharmaceutical researchers from understanding GPCR structures and hampered
efforts to design medicines that work on GPCR targets.

This collaboration brings together Heptares’ GPCR discovery
expertise and proprietary technologies, including its StaR® technology, which
engineers stabilized receptors allowing GPCRs to be investigated, with
AstraZeneca’s biopharmaceutical discovery, development and commercial
capabilities. Research conducted under the collaboration will focus on a number
of specific GPCR targets linked to central nervous system/pain,
cardiovascular/metabolic and inflammatory disorders from projects in
AstraZeneca’s small and large molecule portfolio, including projects from
AstraZeneca’s biologics unit, MedImmune. This research will act as the starting
point for drug discovery by producing the first-ever stabilized forms of GPCRs
in their natural pharmacological conformation.

As part of a joint discovery effort, Heptares and
AstraZeneca will engage their respective discovery teams, compound libraries,
and other discovery technologies for the purposes of initial screening and lead
identification. Results will be combined into a common pool and the best leads
will be further optimised collaboratively.  AstraZeneca will then select
pre-clinical, small and large molecule candidates and will be solely
responsible for preclinical and clinical development.

Under the terms of the agreement, AstraZeneca has worldwide
commercial rights to product candidates emerging from the collaboration. Heptares
will receive an upfront $6.25 million cash payment fee plus committed research
funding and also qualifies for significant future payments depending on
delivery of agreed milestones. Heptares will also receive royalties on sales of
all products discovered through the joint research.

“This exciting collaboration gives us access to
cutting-edge technology that will enable us to apply our biophysical and
antibody generation capabilities to this important, yet extremely challenging,
area of research. Our work will focus on a range of different diseases across
our small and large molecule portfolio with the goal of discovering innovative
treatments for patients in areas of medical need,” said Martin Mackay,
President, Research and Development, AstraZeneca.

“This alliance with AstraZeneca illustrates the broad
power and scalability of the Heptares technology to generate novel drug
candidates in regions of GPCR space that were previously regarded as closed to
pharmaceutical discovery,” said Malcolm Weir, CEO of Heptares. “We
look forward to working closely with our AstraZeneca colleagues to extend the
range of targets and therapeutic areas to which we apply our GPCR capabilities,
and are excited by the significant R&D commitment of AstraZeneca to this
pioneering GPCR alliance.”

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE